| __timestamp | Insmed Incorporated | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 31073000 | 675200000 |
| Thursday, January 1, 2015 | 43216000 | 771800000 |
| Friday, January 1, 2016 | 50679000 | 1205500000 |
| Sunday, January 1, 2017 | 79171000 | 1146500000 |
| Monday, January 1, 2018 | 168218000 | 1125800000 |
| Tuesday, January 1, 2019 | 210796000 | 1166100000 |
| Wednesday, January 1, 2020 | 203613000 | 1175500000 |
| Friday, January 1, 2021 | 234273000 | 1111400000 |
| Saturday, January 1, 2022 | 265784000 | 1210100000 |
| Sunday, January 1, 2023 | 344501000 | 1274600000 |
Unveiling the hidden dimensions of data
In the competitive landscape of the pharmaceutical industry, managing operational costs is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Insmed Incorporated and Perrigo Company plc from 2014 to 2023. Over this period, Perrigo consistently outspent Insmed, with its SG&A expenses peaking at approximately $1.27 billion in 2023, a 90% increase from 2014. In contrast, Insmed's expenses grew more dramatically, surging by over 1,000% to reach $344 million in 2023. This stark difference highlights Perrigo's established market presence and Insmed's rapid growth trajectory. Understanding these trends offers valuable insights into each company's strategic priorities and operational efficiencies. As the industry evolves, monitoring such financial metrics will be key to predicting future market leaders.
Operational Costs Compared: SG&A Analysis of Novo Nordisk A/S and Perrigo Company plc
Comparing SG&A Expenses: Zoetis Inc. vs Perrigo Company plc Trends and Insights
Cost Management Insights: SG&A Expenses for GSK plc and Perrigo Company plc
Insmed Incorporated vs Halozyme Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Insmed Incorporated and Pharming Group N.V.
Insmed Incorporated and Opthea Limited: SG&A Spending Patterns Compared
Comparing Cost of Revenue Efficiency: Insmed Incorporated vs Perrigo Company plc
Insmed Incorporated and Ligand Pharmaceuticals Incorporated: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of TG Therapeutics, Inc. and Perrigo Company plc
Perrigo Company plc and Merus N.V.: SG&A Spending Patterns Compared
Perrigo Company plc and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Perrigo Company plc and Ligand Pharmaceuticals Incorporated